JP6386053B2 - Hair growth or hair growth promoting composition containing 21-O-angeloyl theasapogenol E3 - Google Patents

Description

  In one aspect, the present invention relates to a composition for promoting hair growth or hair growth, and in another aspect, includes 21-O-angeloylteaasapogenol E3, The present invention relates to a composition for promoting hair growth or hair growth, which accelerates hair growth by shortening the period of transition from the rest period to the growth period.

  The causes of hair loss have been discussed, such as male hormone overactivity theory, excessive sebum secretion theory, poor blood circulation theory, hypoxia, hypothesis of scalp function due to bacteria, genetic factors, aging, stress, and the like. In addition to this, along with the increase in social stress, the hair loss population is gradually increasing due to environmental pollution and westernized eating habits such as instant foods, frequent perms and dyeing. The period of the hair is the growth period (anagen) in which the hair grows, the regression period (catagen) in which the growth ends and the hair bulb shrinks, and the time in which the hair papilla stops its activity and the hair stays on the scalp Can be divided into the genus, which is the time when the dermal papilla begins to act, or when new hair is generated and the old hair is removed.

  Growth stage (Anagen Stage; 2 to 7 years) is a period in which hair grows, in which hair is about to come out of the hair bulb into the hair follicle, and in which hard keratin is made in the hair follicle. It is divided into. The hair continues to grow until the regression phase. The regression phase (Catagen Stage; 2-3 weeks) is the period when the growth phase ends and the metabolic process slows down while maintaining the shape of the hair. At this stage, no keratin is produced. The regression phase accounts for 1% of the total hair. At this time, the hair bulb part contracts and separates from the hair papilla, is covered with the hair follicle and moves upward, and cell division is stopped. In the resting period (Talogen Stage; 3 months), the hair papilla shrinks, the hair follicle gradually shrinks, and the hair root is pushed upward and comes off. This is the time when the hair disappears, and the lifetime until the next growth phase begins is 3-4 months.

  A normal person has more hair in the growth phase, and a person with alopecia (Alopecia) has more hair in the resting state, and a visible hair loss phenomenon appears. As hair removal progresses, the period of the growth phase is shortened, which makes the hair increasingly smaller. Therefore, for the treatment of hair loss, it is important to allow the hair follicles in the resting state to proceed promptly to the growth phase and increase the shortened growth phase.

  Male pattern alopecia is a phenomenon manifested by a male hormone called Testosterone. When this testosterone is changed to dihydrotestosterone (DHT), which is a more powerful hormone, by an enzyme called 5α-reductase. This hormone acts on the hair follicle and induces the hair follicle from the growth phase to the regression phase, causing hair loss. Therefore, methods for inhibiting DHT production by 5α-reductase are mainly used to treat androgenetic alopecia.

  Female pattern alopecia occurs mainly due to a decrease in postmenopausal estrogen levels. Minoxidil and estrogen are mainly used as therapeutic agents for female pattern alopecia.

  Alopecia areata is caused by autoimmune diseases, mental stress, and genetic predisposition. These alopecia areata are fundamentally different from androgenetic alopecia, and the treatment methods are also different, so it is possible to use a method of treating corticosteroids, apply minoxidil to the affected area, artificially affect the affected area Use methods to induce stimulation.

  However, in the case of preparations such as minoxidil and trichosaccharide, which have been known to be effective in preventing hair loss and promoting hair growth and hair growth, there is no clear lack of efficacy. In addition, since problems of side effects such as stability of human body and induction of skin irritation are emerging, development of a composition that ensures safety and efficacy is urgent.

  In order to solve the above problems, the present invention is characterized in that, in one aspect, 21-O-angeloylteasapogenol E3 has a hair growth or hair growth promoting effect that has not been known so far. It is an object of the present invention to provide a cosmetic composition, a pharmaceutical composition and a health food composition that are discovered and utilized.

  In one aspect, the present invention provides a composition for promoting hair growth or hair growth, which contains a theasapogenol derivative represented by the following chemical formula 1 as an active ingredient.

In the above formula, R ₁ and R ₂ are each independently —H, C _1-6 alkyl, —OH, —R ₆ OH or —CHO,
R ₃ is —H, C _1-6 alkyl, —OH or —OOCR ₇ ;
R ₄ is —H or —COR ₈ ;
R ₅ is —H or C _1-6 alkyl;
Here, R ₆ is C _1-6 alkyl, R ₇ is C _2-6 alkenyl, and R ₈ is C _1-6 alkyl.

  In another aspect, the present invention provides a composition for promoting hair growth or hair growth comprising 21-O-angeloyltheasapogenol E3 as an active ingredient.

  According to another aspect of the present invention, a theasapogenol derivative derived from green tea saponin is used as an active ingredient, and in one aspect, the active ingredient is contained in an amount of 0.001 to 20% by weight based on the total weight of the composition. A composition for promoting hair or hair growth is provided.

  In another aspect, the present invention provides a composition for promoting hair growth or hair growth, which is a cosmetic composition, pharmaceutical composition or food composition.

  In one aspect, the composition of the present invention exhibits 21-O-angeloylteasapogenol E3 derived from green tea saponin, thereby exhibiting a hair growth or hair growth promoting effect superior to conventional hair restorers. be able to.

  In addition, because it uses plant natural products, it is excellent in safety, so it can be used as a skin external preparation for promoting hair growth and hair growth, and is a cosmetic composition, pharmaceutical composition, health food composition, etc. Can be widely used for.

  In another aspect, the composition containing 21-O-angeloylteasapogenol E3 as an active ingredient has an effect of proliferating hair follicle dermal papilla cells, and is a potentiator of PGE2, IL-6, and IL-8. An effect of suppressing generation can be expressed.

  Korean Patent Application No. 10-2013-0104230 filed on August 30, 2013 is hereby incorporated by reference in its entirety for all purposes. In addition, this application claims the benefit of Korean Patent Application No. 10-2013-0104230, which is incorporated herein by reference in its entirety.

In the following, the present invention will be described in detail.
In one aspect, the composition of the present invention is a composition for promoting hair growth or hair growth, which contains a theasapogenol derivative represented by the following chemical formula 1 as an active ingredient.

  In one aspect, the present invention relates to a method for promoting hair growth or hair growth, comprising administering a theasapogenol derivative represented by the following chemical formula 1 to an individual in need of hair growth or hair growth promotion. The administration may be in accordance with the administration method or dosage described herein.

  In one aspect, the present invention relates to a hair growth or hair growth promoting application of a theasapogenol derivative represented by the following chemical formula 1.

  In one aspect, the present invention relates to a theasapogenol derivative represented by the following chemical formula 1 for use in hair growth or hair growth promotion.

In the above formula, R ₁ and R ₂ are each independently —H, C _1-6 alkyl, —OH, —R ₆ OH or —CHO,
R ₃ is —H, C _1-6 alkyl, —OH or —OOCR ₇ ;
R ₄ is —H or —COR ₈ ;
R ₅ is —H or C _1-6 alkyl;
Here, R ₆ is C _1-6 alkyl, R ₇ is C _2-6 alkenyl, and R ₈ is C _1-6 alkyl.

  In another aspect, the composition of the present invention is a composition for promoting hair growth or hair growth comprising 21-O-angeloyl theasapogenol E3.

  In one aspect, the present invention may relate to a method for promoting hair growth or hair growth, comprising administering 21-O-angeloylteasapogenol E3 to an individual in need of hair growth or hair growth promotion. The administration may be in accordance with the administration method or dosage described herein.

  In one aspect, the present invention may relate to a hair growth or hair growth promoting application of 21-O-angeloylteasapogenol E3.

  In one aspect, the present invention may relate to 21-O-angeloylteasapogenol E3 for use in hair growth or hair growth promotion.

In another aspect, the 21-O-angeloylteasapogenol E3 may be represented by the following chemical formula 2. That is, the following chemical formula 2 is the formula 1, wherein R ₁ is —CHO, R ₂ is —CH ₃ , R ₃ is —OCOC (CH ₃ ) ═CHCH ₃ , R ₄ is —COCH ₃ , and R ₅ is — Corresponds to a theasapogenol derivative that is CH ₃ .

  In another aspect, the theasapogenol derivative represented by Chemical Formula 1 or 21-O-angeloyl theasapogenol E3 may be 21-O-angeloyltheasapogenol E3 derived from green tea saponin. . 21-O-Angeloylteasapogenol E3 derived from green tea saponin is obtained from green tea seeds using water or an organic solvent to obtain an extract containing saponin; Alternatively, it may be produced through a production method including a step of separating 21-O-angeloylteasapogenol E3 by hydrolysis using an enzyme or a microorganism producing the enzyme.

  The organic solvent may be one or more organic solvents selected from the group comprising ethanol, methanol, butanol, ether, ethyl acetate, and chloroform, or a mixture thereof and water. In one aspect, 50% ethanol may be used. The acid is one or more acids selected from the group consisting of hydrochloric acid, sulfuric acid and nitric acid, or a mixed solvent of the acid and one or more alcohols selected from the group consisting of ethanol, methanol and butanol. It's okay. The base is one or more bases selected from the group consisting of sodium hydroxide and potassium hydroxide, or a mixed solvent of the base and one or more alcohols selected from the group consisting of ethanol, methanol, and butanol. May be used. The enzyme or the microorganism that produces the enzyme is an microorganism that produces an enzyme that degrades the sugar bond of green tea saponin contained in the extract or an enzyme that degrades the sugar bond, and removes the sugar portion of the green tea saponin. 21-O-angeloyl theasapogenol E3 can be produced. The enzymes include glucosidase, arabinosidase, rhamnosidase, xylosidase, cellulase, hesperidinase, naringase, naringase, naringase, It may be one or more selected from the group consisting of pectinase, galactosidase, and amyloglucosidase. In addition, the microorganisms that produce the enzyme include the genera Aspergillus, Bacillus, Penicillium, Rhizopus, Rhizomucor, Talaromyces, and Talaromyces. It may be one or more selected from the group consisting of the genus (bifidobacterium), the genus Mortierella, the genus cryptococcus, and the genus microbacterium.

  As described above, after hydrolysis using acid, base, enzyme, or microorganism producing the enzyme, the reaction solution is concentrated under reduced pressure to remove the solvent, and alcohol is added to the residue and stirred 1 to 5 times. Then, precipitated salts and the like are removed through filtration, and the filtrate is concentrated under reduced pressure to obtain a crude product. The obtained crude product is subjected to silica gel column chromatography (chloroform: methanol = 8: 1). ˜4: 1) to obtain 21-O-angeloylteasapogenol E3.

  In one aspect, Korean Patent Application No. 10-2008-0088127 relating to a method for producing 21-O-angeloylteasapogenol E3 derived from green tea saponin is incorporated herein by reference in its entirety.

  In one aspect, the composition disclosed herein comprises 0.001 to 20% by weight of the theasapogenol derivative represented by Formula 1 or 21-O-angeloylteasapogen based on the total weight of the composition. Nord E3 may be contained, and in another aspect, 0.01 to 15 wt%, 0.01 to 10 wt%, or 0.1 to 5 wt% may be contained. In one aspect, the theasapogenol derivative represented by Formula 1 or 21-O-angeloylteasapogenol E3 contained in the composition disclosed herein is 0.001 weight based on the total weight of the composition % Or more, 0.01% or more, 0.1% or more, or 1.0% or more, and in another aspect, 20% or less, 15% or less, 10% or less, Or it may be 5 weight% or less. When the content is less than 0.001% by weight, the effect of promoting hair growth or hair growth of the composition cannot be expected, and when the content exceeds 20% by weight, it is necessary for safety or dosage form production. Although it is difficult, the content is not particularly limited.

  The composition disclosed in the present specification, in one aspect, includes a theasapogenol derivative represented by Chemical Formula 1 or 21-O-angeloylteasapogenol E3, and has an effect of proliferating hair follicle papilla cells It can be a thing. In another aspect, the composition disclosed herein comprises a theasapogenol derivative represented by Formula 1 or 21-O-angeloylteasapogenol E3, and activates keratinocytes. It may be.

  In another aspect, the composition disclosed herein includes a theasapogenol derivative represented by Formula 1 or 21-O-angeloylteasapogenol E3, wherein PGE2, IL-6, or IL-8 It may be a composition having an effect of suppressing generation.

  In one aspect, the composition for promoting hair growth or hair growth of the present invention may be a pharmaceutical composition, a cosmetic composition, or a health food composition.

  The cosmetic composition for promoting hair growth or hair growth according to one embodiment of the present invention includes functional additives and general additives other than the theasapogenol derivative represented by Chemical Formula 1 or 21-O-angeloylteasapogenol E3. Ingredients included in a typical cosmetic composition may be further included. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids, and seaweed extracts.

  Moreover, you may mix | blend the component contained in a general cosmetic composition with the said functional additive with the cosmetic composition of this invention as needed. Other ingredients included are oil and fat ingredients, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, fungicides, antioxidants, plant extracts, pH Examples include regulators, alcohols, pigments, fragrances, blood circulation promoters, cooling sensates, antiperspirants, and purified water.

  The cosmetic composition for promoting hair growth or hair growth according to one embodiment of the present invention is not particularly limited in dosage form, and may be appropriately selected according to the intended purpose. For example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing foam, It may be manufactured in any one or more dosage forms selected from the group consisting of cleansing lotion, cleansing cream, body lotion and body soap, but is not limited thereto.

  When the dosage form of the present invention is a paste, cream or gel, the carrier component is animal fiber, vegetable fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicon, bentonite, silica, talc or oxidized Zinc or the like may be used.

  When the dosage form of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, especially in the case of a spray. Propellants such as fluorohydrocarbons, propane / butane or dimethyl ether may be included.

  When the dosage form of the present invention is a solution or an emulsion, a solvent, a solvating agent or an emulsifying agent may be used as a carrier component. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, There are benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.

  When the dosage form of the present invention is a suspension, the carrier component is a liquid diluent such as water, ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester. Agents, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth may be used.

  When the dosage form of the present invention is a surfactant-containing cleansing, as a carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, Sarcosinates, fatty acid amide ether sulfates, alkylamide betaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters may be used.

  The content of the theasapogenol derivative represented by Chemical Formula 1 or 21-O-angeloylteasapogenol E3, which is an active ingredient contained in the cosmetic composition, is not particularly limited, but is 0 based on the total weight of the composition. 0.001 to 20 wt%, and in another aspect 0.01 to 15 wt%, 0.01 to 10 wt%, or 0.1 to 5 wt%. When the said active ingredient satisfy | fills the said content, the outstanding effect can be expressed without a side effect.

  The pharmaceutical composition for promoting hair growth or hair growth according to one embodiment of the present invention comprises a preservative, a stabilizer, water, in addition to the theasapogenol derivative represented by Chemical Formula 1 or 21-O-angeloylteasapogenol E3. It may further contain hydrating agents, emulsifying agents, pharmacological adjuvants such as salts and / or buffers for regulating osmotic pressure, and other therapeutically useful substances, and various oral administrations according to conventional methods The dosage form may be in the form of an agent or a parenteral agent.

  Examples of the oral administration agent include tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, powders, powders, fine granules, granules, pellets, and the like. In addition to the active ingredient, the form includes surfactants, diluents (eg lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (eg silica, talc, stearic acid and its magnesium or calcium salts) As well as polyethylene glycol). Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally disintegrating agents such as starch, agar, alginic acid or its sodium salt, Pharmaceutical additives such as absorbents, colorants, flavoring agents, and sweeteners may be included. The tablets may be manufactured by conventional mixing, granulating or coating methods.

  The parenteral dosage form may be a transdermal dosage form such as an injection, infusion, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, etc. The dosage form may be, but is not limited to these.

  The pharmaceutical composition according to one embodiment of the present invention may be administered parenterally, rectally, topically, transdermally, subcutaneously, and the like. The pharmaceutical composition according to one embodiment of the present invention may be locally administered to the scalp, for example.

  Determination of the dose of the active ingredient is within the level of those skilled in the art, and the daily dose of the drug varies depending on the degree of hair loss progression, onset time, age, health status, complications, etc. of the subject to be administered. Although it depends on factors, in the case of adults as a reference, the composition is divided into 1 μg / kg to 200 mg / kg in one aspect and 50 μg / kg to 50 mg / kg in one aspect divided into 1 to 3 times a day. The dosage is not intended to limit the scope of the invention in any way.

  Further, the composition for promoting hair growth and hair growth according to one embodiment of the present invention may be an external preparation for skin, and the external preparation for skin may be included in any form applied outside the skin. It is a generic term and may include cosmetics and pharmaceuticals in various dosage forms.

  In the health food composition according to one embodiment of the present invention, the composition may be in a liquid or solid dosage form, and is a tablet, capsule, soft capsule, pill, granule, beverage (drink agent) ), Diet bar, chocolate, caramel dosage form or confectionery dosage form, and the dosage form is not particularly limited. In addition to the active ingredient 21-O-angeloylteasapogenol E3, the health food composition of the present invention appropriately contains excipients, saccharides, fragrances, pigments, oils and fats, proteins and the like as necessary. May be included.

  The content of theasapogenol derivative represented by chemical formula (1) or 21-O-angeloylteasapogenol E3, which is an active ingredient contained in the health food composition, is not particularly limited, but is based on the total weight of the composition It may be 0.001 to 20% by weight, and in another aspect may be 0.01 to 15% by weight, 0.01 to 10% by weight, or 0.1 to 5% by weight. When the said active ingredient satisfy | fills the said content, the outstanding effect can be expressed without a side effect.

  The present invention will be described in more detail through the following examples. However, the examples are for illustrating the present invention, and the scope of the present invention is not limited to these examples.

[Production Example 1] Manufacture of 21-O-angeloylteasapogenol E3 derived from green tea saponin 6 kg of hexane was added to 2 kg of green tea seeds, stirred and extracted at room temperature, and then defatted, 1 kg of defatted green tea seeds 4 liters of 50% ethanol was added to the solution, and the mixture was extracted by refluxing three times and then immersed at 15 ° C. for 1 day. Thereafter, the residue and the filtrate are separated through filtration with a cloth filter and centrifugal separation, and the extract obtained by concentrating the separated filtrate under reduced pressure is suspended in water, and then extracted 5 times with 1 liter of ether to remove the pigment. The aqueous layer was extracted 3 times with 500 ml of 1-butanol. The total 1-butanol layer obtained from this was concentrated under reduced pressure to obtain 1-butanol extract, which was dissolved in a small amount of methanol, added to a large amount of ethyl acetate, and the resulting precipitate was dried. 300 g of green tea seed extract was obtained.

  To 10 g of the obtained green tea seed extract, 20 times (v / w) 1N HCl-50% methanol solution (v / v) is added and heated to reflux in an 80 ° C. water bath for 8 hours to obtain green tea seed crude saponin. The sugar bound to was hydrolyzed. The reaction solution was concentrated under reduced pressure to remove the solvent. Ethanol (200 ml) was added to the residue and stirred (3 times), and then the precipitated salt and the like were removed through filtration. The filtered filtrate was concentrated under reduced pressure to obtain a crude product. After obtaining the product, the obtained crude product was separated by silica gel column chromatography (chloroform: methanol = 7: 1 to 3: 1) to give 21-O-angeloylteasapogenol E3 0.55. Was obtained. Using Varian Gemini 2000 300 MHz (Varian), it was confirmed that the obtained product was 21-O-angeloylteasapogenol E3. Korean Patent Application No. 10-2008 referred to in this specification is used. The same results as in Experimental Example 1 in the detailed description of the invention of -0088127 were obtained.

[Test Example 1] Expression evaluation of hair growth factor VEGF in dermal papilla cells 21-O-angeloylteasapogenol E3 is a growth factor necessary for angiogenesis and is required to move to the hair growth phase In order to evaluate the degree of expression of the growth factor vascular endothelial growth factor (VEGF), an in vitro system was applied to apply 21-O-angeloyltea derived from green tea saponin. The activity after application of sapogenol E3 was evaluated.

For the experiment, 47-year-old male dermal papilla dermal cells (DPC) (P.11) 4 × 10 ⁵ cells were seeded into a 12-well plate, 10 The cells were cultured overnight in DMEM (Dulbecco's modified Eagle's medium) medium containing% FBS (fetal bovine serum). After the cultivation, 21-O-angeloylteasapogenol E3 derived from green tea saponin was treated with 20 ppm. DMSO was used as a negative control group. 24 hours later, a mixed solution treated with 21-O-angeloylteasapogenol E3 derived from green tea saponin was collected (soap collect), and VEGF ELISA (Vascular endogenous growth factor & Linked ImmediateRimbsorbyImmunosbMimsorbentImmunsorbentImmunosminDimRimbMimBossImmunBossImmunBossImmunBossImmunBossImmunBossImmunBossImmunoBloodImmunoSimogen) Was used to confirm the expression level of 21-O-angeloylteasapogenol E3 derived from green tea saponin. The results are shown in Table 1.

  As can be seen from Table 1, it can be confirmed that 21-O-angeloylteasapogenol E3 derived from green tea saponin showed a large difference in effect compared with the control group, Increased the expression of hair growth factor VEGF in about 3 times or more. Therefore, it can be seen that 21-O-angeloylteasapogenol E3 derived from the green tea saponin according to the present invention has an excellent ability to promote hair generation.

[Test Example 2] Evaluation of hair follicle dermal papilla cell proliferation effect Keratin protein constituting hair is produced by hair root keratinocytes, and these keratinocytes are differentiated from dermal papilla cells. Therefore, if 21-O-angeloylteasapogenol E3 derived from the green tea saponin according to the present invention promotes the activity of hair papilla cells, the activity of keratinocytes differentiated therefrom can be promoted. , And thus hair production could be promoted.

  Therefore, in this experiment, the effect of 21-O-angeloylteasapogenol E3 derived from green tea saponin on promoting dermal papilla cell activity was evaluated as follows.

First, in this experiment, a human hair papilla cell (Human derma papilla cell, Seoul National University, Professor Gongosho) cell line was used. The cell lines, Dulbecco's were contained 10% fetal bovine serum (FBS) modified Eagle's medium (DMEM ; Gibco BRL, Gaithersburg, MD, USA) in is maintained at 5% _CO 2, 37 ℃ After culturing in an incubator for 24 hours, 21-O-angeloylteasapogenol E3 derived from green tea saponin was treated with 1 ppm, 10 ppm and 20 ppm, respectively. DMSO was used as a negative control group. After the treatment of the test substance, 24 hours later, the cell proliferation ability (%) was measured using the WST-1 kit (Roche). The results are shown in Table 2.

  As can be seen from Table 2, 21-O-angeloylteasapogenol E3 derived from the green tea saponin according to the present invention significantly increased the proliferation of the two cells at both 10 ppm and 20 ppm. In particular, when 20 ppm of 21-O-angeloylteasapogenol E3 derived from green tea saponin was treated with 20 ppm, the growth rate of hair papilla cell proliferation was about 1.5 times higher than that of the control group. This is because 21-O-angeloylteasapogenol E3 derived from the green tea saponin according to the present invention can promote the proliferation of hair papilla cells, and the activity of keratinocytes and the generation of hair are also more effective. Means that can be promoted.

[Test Example 3] Evaluation of hair growth promoting effect using human hair follicle organ An experiment was conducted in which the hair growth promoting ability of an actual human hair follicle organ according to the present invention was confirmed.

  Hair follicle organs were isolated one by one from a 55-year-old male occipital scalp tissue, and William E medium (L-glutamine (2 mM), insulin (10 μg / ml), hydrocortisone (40 ng / ml), antibiotics (1% ) And an antifungal agent (containing 1%). The hair follicles that grew on the third day after the culture were selected and cut into 3 mm, and the selected hair follicle tissue was treated with 21-O- derived from green tea saponin as a control group. Angeloylteaasapogenol E3 1 ppm, 3 ppm and 5 ppm were treated, respectively. And 8 days after processing, each length was measured and photographed. The results are shown in Table 3.

  As a result, as can be seen from Table 3, in the increase in hair length in the hair follicle organs, when 5 ppm of 21-O-angeloylteasapogenol E3 derived from green tea saponin was treated, compared to the control group Excellent hair growth promoting effect was shown. Accordingly, when looking at the results in Table 3, the 21-O-angeloylteasapogenol E3 derived from the green tea saponin according to the present invention is excellent in the effect of promoting hair length growth in the hair follicle. I understand.

[Test Example 4] PGE2, IL-6, and IL-8 production inhibition experiment Human fibroblasts were inoculated into a 6-well culture plate at a cell concentration of 1 × 10 ⁵ and maintained at 37 ° C. and 5% CO _{2 for} 24 hours. Cultured in an incubator. The wells were treated with 500 μM H ₂ O ₂ and stimulated for 24 hours, and then the calcium tree extract was treated according to concentration and reacted for 48 hours. After completion of the reaction, the culture solution was collected and subjected to ELISA analysis. At this time, α-bisabolol, which is a substance frequently used as an anti-inflammatory and stimulating agent, was used as a control group. PGE2 was assayed using Assay Design kit, IL-6 and IL-8 were using Endogen kit, and experiments were performed according to the methods specified in each company's manual. The suppression effect was calculated based on Equation 1 below, and the measurement results are shown in Table 4 below.

  As shown in Table 4 below, the amount of inflammation mediators PGE2, IL-6, and IL-8 produced was 21-O-angeloylteasapogenol E3 derived from the green tea saponin of the present invention. It can be confirmed that it is remarkably reduced by addition and shows a high inhibitory effect.

[Formula 1]
Inhibitory effect = {1- (test sample-control group) / (H ₂ O ₂ -control group)} × 100

  Examples of dosage forms of the composition according to the present invention will be described below. However, the present invention can be applied to various other dosage forms, and this is not intended to limit the present invention, but only specifically. It is something to try.

[Dosage Form Example 1] Shampoo According to the composition described in Table 5 below, a shampoo was produced by an ordinary method.

[Dosage Form Example 2] Rinse According to the composition described in Table 6 below, a rinse was produced by an ordinary method.

[Dosage Form Example 3] Ointment An ointment was produced by a conventional method according to the composition described in Table 7 below.

[Dosage Form Example 4] Hair Tonic According to the composition described in Table 8 below, a hair tonic was produced by an ordinary method.

[Dosage Form Example 5] Hair Lotion According to the composition described in Table 9 below, a hair lotion was produced by an ordinary method.

[Dosage Form Example 6] Hair Soap According to the composition described in Table 10 below, a hair soap was produced by an ordinary method.

[Dosage Form Example 7] Lotion According to the composition described in Table 11 below, a lotion was produced by an ordinary method.

[Dosage Form Example 8] Cream According to the composition described in Table 12 below, a cream was produced by an ordinary method.

[Dosage Form Example 9] Pack According to the composition described in Table 13 below, a pack was produced by an ordinary method.

[Dosage Form Example 10] Cosmetic liquid formulation A cosmetic liquid formulation was produced in the usual manner according to the composition described in Table 14 below.

[Formulation Example 11] Soft Capsule Theasapogenol derivative represented by Chemical Formula 1 or 21-O-angeloylteasapogenol E3 50 mg, L-carnitine 80-140 mg, soybean oil 180 mg, palm oil 2 mg, vegetable hardened oil 8 mg, 4 mg of yellow wax and 6 mg of lecithin were mixed, and 400 mg per capsule was filled according to a normal method to produce soft capsules.

[Dosage Form Example 12] Purification A theasapogenol derivative represented by the chemical formula 1 or 21-O-angeloylteasapogenol E3 50 mg, galactooligosaccharide 200 mg, lactose 60 mg and maltose 140 mg are mixed, using a fluid bed dryer. After granulation, 6 mg of sugar ester was added and tableted by a tableting machine to produce tablets.

[Formulation Example 13] Granules Theasapogenol derivative represented by Chemical Formula 1 or 21-O-angeloylteasapogenol E3 50 mg, anhydrous crystalline glucose 250 mg and starch 550 mg were mixed, and using a fluid bed granulator. After forming into granules, the capsules were filled to produce granules.

[Formulation Example 14] Drink agent After mixing 50 mg of theasapogenol derivative or 21-O-angeloylteasapogenol E3 represented by chemical formula 1, glucose 10 g, citric acid 0.6 g and liquid oligosaccharide 25 g, purified water 300 ml was added and 200 ml was filled into each bottle. After filling the bottle, it was sterilized at 130 ° C. for 4 to 5 seconds to produce a drink beverage.

Claims (8)

A composition containing 21-O-angeloyltheasapogenol E3 as an active ingredient ,
The composition contains the 21-O-angeloyltheasapogenol E3 in an amount of 0.001 to 20% by weight based on the total weight of the composition. Accelerating composition. The composition for promoting hair growth or hair growth according to claim 1 , wherein the 21-O-angeloylteasapogenol E3 is represented by the following chemical formula 2.

  The composition for promoting hair growth or hair growth according to claim 1, wherein the active ingredient is derived from green tea saponin.   The composition for promoting hair growth or hair growth according to claim 1, wherein the composition has an effect of proliferating hair follicle papilla cells.   The composition for promoting hair growth or hair growth according to claim 1, wherein the composition has an effect of suppressing production of PGE2, IL-6 or IL-8. The composition for promoting hair growth or hair growth according to any one of claims 1 to 5 , wherein the composition is a cosmetic composition. The composition for hair growth or hair growth promotion according to any one of claims 1 to 5 , wherein the composition is a pharmaceutical composition. The composition for hair growth or hair growth promotion according to any one of claims 1 to 5 , wherein the composition is a food composition.